Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access Is Easy. Choosing the Right ETF Is Not

With 1,790 launches through July 2026, finding an ETF is easy and choosing one is not. 46% of share classes hold under $50 million, and nearly 7 in 10 allocators are reassessing their holdings, with portfolio fit the top criterion. See how 620 professionals select ETFs.

Trackinsight Global ETF Survey 2026
›ETF Issuers›Global X›09820
09820

Global X China Biotech ETF

Passive ETFEquity
Not rated

The 09820 Exchange Traded Fund (ETF) is provided by Global X. It is built to track an index: Solactive China Biotech Index. The 09820 ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

-
-
-
1D price range
N/A
52W price range
N/A
YTD Perf.
-
YTD Flows
Annualized volatility
Fund AuM
€0
Share class AuM
€0
TTM Yield
Tracking Error
Tracking Difference
ISIN
HK0000516697HK0000516689
TER
0.68%
Inception date
7/25/2019
Issuer
Replication method
Dividend policy
Compare similar ETFs

Data will be available soon for this fund

Data as of 08/31/26
Healthcare
99.69%
Unavailable
0.31%
Latest 09820 news

No content available for this fund

FAQ about 09820

09820 is a Passive ETF. This ETF provides exposure to Chinese Biotechnology Equities.
09820 tracks the Solactive China Biotech Index - CNY, through a full replication replication method.
09820 carries a total expense ratio (TER) of 0.68%, indicating the annual cost for holding the fund.
09820 was introduced to the market on July 25, 2019. It trades on Hong Kong
Global X China Biotech ETF, 09820, is provided by Global X. Learn more about Global X here.
09820 follows a distributing dividend policy, meaning it pays out income to investors.
As of August 31, 2026, 09820 has significant geographic allocations in China, Switzerland and Hong Kong.
As of August 31, 2026, 09820 focuses largely on Healthcare.
As of August 31, 2026, 09820 holds 30 positions in its portfolio, with 80.29% of assets concentrated in its top 15 holdings.
As of August 31, 2026, 09820 top three holdings include WuXi Biologics (Cayman), Inc., WuXi AppTec Co., Ltd. and BeOne Medicines Ltd..
The base currency of 09820 is CNY.
Data as of 08/31/26
WuXi Biologics (Cayman), Inc.
10.82%
WuXi AppTec Co., Ltd.
10.41%
BeOne Medicines Ltd.
9.95%
Innovent Biologics, Inc.
9.72%
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
6.92%
Akeso, Inc.
5.68%
Sino Biopharmaceutical Ltd.
4.30%
Hansoh Pharmaceutical Group Co., Ltd.
3.97%
Genscript Biotech Corp.
3.33%
Pharmaron Beijing Co., Ltd.
3.13%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight